OPCML Antibodies

Opioid-binding protein/cell adhesion molecule (OPCML)

Binds opioids in the presence of acidic lipids; likely involved in cell contact. .

Gene Information

Human
Gene Name:	OPCML
Uniprot:	Q14982
Entrez:	4978

Family

Belongs to:
immunoglobulin superfamily

Alternative Names

IgLON family member 1; IGLON1opioid-binding protein/cell adhesion molecule-like; OBCAM; OBCAMopiate binding-cell adhesion molecule; OPCM; OPCML; opioid binding protein/cell adhesion molecule-like preprotein; opioid binding protein/cell adhesion molecule-like; Opioid-binding cell adhesion molecule; opioid-binding protein/cell adhesion molecule

Molecular Weight

Mass (kDA):
38.008 kDA

Genomic Context

Human
Location:	11q25
Sequence:	11; NC_000011.10 (132403361..133532534, complement)

Subcellular Localizations

Cell membrane; Lipid-anchor, GPI-anchor.

Diseases

• Tissue Adhesions
• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Ovarian Neoplasm
• Malignant Neoplasm Of Ovary
• Epithelial Ovarian Cancer
• Nervousness
• Malignant Neoplasm Of Lung
• Neoplasm Metastasis
• Carcinogenesis
• Lung Neoplasms
• Neuroblastoma

• Lymphatic Metastasis
• Glioma
• Cell Transformation, Neoplastic
• Cholangiocarcinoma
• Adenocarcinoma
• Neoplasm Recurrence, Local
• Liver Carcinoma

Pathways

• Cell Adhesion
• Methylation
• Localization
• Dna Methylation
• Dna Hypermethylation
• Demethylation
• Cell Proliferation
• Cell-cell Recognition
• Gene Silencing
• Glycosylation
• Dna Hypomethylation
• Endocytosis
• Ovulation

• Axon Guidance
• Cellular Localization
• Cell Cycle
• Hatching
• Cell Growth
• Pathogenesis
• Exocytosis

PTMs

• Methylation
• Glycosylation

• Demethylation
• Ribosylation

• Deglycosylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/OPCML

Best Uses Of The OPCML Marker

Scientists all over the globe are developing new ways to use OPCML Marker. This article describes the various ways scientists can control the expression of this marker using biological samples. We also discuss the combination of OPCML Marker and other markers. These methods will ultimately help scientists discover better ways to use OPCML Marker in research.

OPCML Marker modulated in a biological sample

OPCML belongs to the IgLON family, which includes GPI-anchored cell adhesion moles. Although it has been implicated in carcinogenesis and gastric cancer, its role remains largely speculative. In this study we investigated the biological behavior, expression and function of OPCML in gastric cancer cells. Here, we describe the mechanism of OPCML modulation.

To analyze OPCML, PCR was done using a primer pairing specific to each of three exons. These primers are designed to amplify the v2 and v3 exons. These primers will amplify the corresponding RNA from the skeletal muscles sample. Table 1 lists the PCR primers needed to amplify these genes.

OPCML genes are down-regulated in primary gastric tumor tissues and healthy stomachs. This suggests that OPCML may be an independent prognosticator for gastric cancer. OPCML's biological behavior supports its role in suppressing gastric cancer. These results support OPCML's role in controlling the cell cycle and the possibility that OPCML may also affect the expression of the gene in gastric cancer.

OPCML genes are highly expressed in the brain, epithelia, and normal ovarian cells. Semi-quantitative DNA PCR and primers that target specific exons were used for the evaluation of this gene in 33 human tissues. OPCMLv1 was detected in all of these tissues except the placenta. The proportion score multiplied by the intensity score was the staining Index.

The OPCML gene is frequently silenced in multiple tumor cell lines and in primary tumors. Ectopic expression of the gene inhibits tumor cell clonogenicity. In addition, ectopic expression of OPCML-v1 inhibited anchorage-dependent growth significantly. These findings are consistent both with previous studies in cancer as well as other types. OPCML gene-ectopic expression is therefore a promising tool in the detection of this protein.

This study showed that OPCML gene transcription is associated with CpG site methylation in ovarian cancer. In addition, the expression of OPCML is associated with the presence of the clinically-relevant clinical parameters in ovarian cancer. These results suggest that OPCML gene transcription may be a risk factor in ovarian cancer. More studies with larger samples will be required to determine if OPCML plays any role in the progression and spread of ovarian carcinoma.

To validate the OPCML genetic methylation marker we performed a series o genomic analyses using OPCML V1 promoter. These results were in line to our expectations. We found that OPCML methylation was frequently detected in lymphoma cells and NPC cells, but not in normal epithelial tissue. Furthermore, we demonstrated that the gene is sensitive to stress, which is a further sign of its role in cancer progression.

OPCML Marker expression from a biological collection

OPCML can suppress multiple types of cancer. It interacts with IgLONs to form a heterodimeric complex and plays an important role in signal transduction. OPCML loss in cancer cells reduces intercellular adhesion, and impairs signaling pathways. It is also often inactivated epigenetically in many types of cancer.

The current study revealed the location and function of OPCML protein within female reproductive systems. The immunoreactivity to the protein was also found within uterine tissues. Further studies are necessary to determine if the protein is also present in tumor cells and in granulosa or granulosa cells. OPCML Marker expression was detected in uterine tissues. For further analysis, researchers recommend further studies at the cellular level.

OPCML has been implicated by bladder cancer due to aberrant promotermethylation. High-resolution bisulfite genome sequence (BGS) has been used to determine the promoter region. A total of 90 CpG locations were analyzed. This covered almost all the predicted promoter. The BGS results were in line with the MSP data. OPCML-v1 methylation levels in bladder tumor samples were correlated to the presence OPCML transcript.

OPCML is part of the IgLON group of cell adhesion proteins. It associates with six different heterodimeric Diglons that inhibit axon migration. OPCML and LSAMP are other members of the IgLON Family. They were also identified as a tumour suppressor gene in ovarian, renal and gastric cancer. OPCML Marker is a powerful indicator of the presence and spread of cancer cells in biological samples.

OPCML gene possesses two splice versions. Homozygous deletions in humans result in the expression of one of the two genes. These variants can all be distinguished using PCR using identical primers. A multiplex genomic DNAPCR was used to test one gene. Table S1 includes the primer sequences. Table S1 lists the primer sequences. The PCR products of each gene were tested on 1.8% agarose gels.

OPCML has been detected in the biological samples of 118 patients with gastric carcinoma. It is associated to unfavorable tumor stage and differentiation degree as well as overall survival. However, gastric cancer cells contain lower levels OPCML M-RNA than normal gastric mucosa. However, RTPCR confirmed that cells transfected pcDNA3.1 with OPCML expressed an aberrantly high level of OPCML. CCK8 and colony-formation assays revealed an inhibition in OPCML expression in these cells.

RNA methylation can be used to monitor molecular markers in biological samples. It can also identify early-stage epithelial and ovarian cancer. It allows for the detection of many genetic changes, including OPCML methylation. This test is highly sensitive and results are sent within one week. The results are extremely promising, as can be seen.

OPCML Marker modulated when used in combination with other markers

OPCML can be described as a protein which is expressed by cells within the human body. The process involves the translation of a gene into an mRNA and then transcription into a protein. The "FC" or "fold-change" ratio of a marker will often indicate its expression. This measurement indicates if the marker has been altered or up-regulated. This information is important in interpreting results from prostate biopsies.

The OPCML Marker and other markers can be combined to make the most of it. This marker may be used in order to detect NASH in a person. It can also help to detect advanced liver diseases such as fibrosis. These markers can be compared to a control sample from an earlier time period, before the patient was diagnosed. A change in a marker's levels is more important than an absolute rise.

OPCML methylation was found to be significantly altered in early-stage EOC and in healthy donors, which supported the hypothesis of specific fcDNA methylation. The CA125 test's k-value was also increased by a methylated OPCML manufacturer to 0.757. This suggests that it may be a better clinical marker than EOC.

OPCML methylation specific polymerase chain reaction is (MSP) a PCR technique that detects methylation of OPCML genes. It is a highly specific marker, as opposed to CA125. This can be used in early-stage EOC to monitor the OPCML genes status. The MSP uses fcDNA (a template) and primer sets were derived from tumor cells and genomes of healthy donors.

OPCML Marker could be used as a predictor in OPCML. This includes alcohol-induced Steatohepatitis, liver cancer, and transplant rejection for patients who have had a liver transplant. The discovery may also be applicable to other organs or diseases that are characterized by fibrosis.